Keyword Search
Legend:
CC = Baltimore Convention Center, H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Sample size returned 55 record(s)
|
|
Monday, 07/31/2017
|
Event Rate Estimation Based on Blinded Time-To-Event Data to Verify Sample Size Calculation Assumptions
Youlan Rao, United Therapeutics Corporation, Durham, NC; Suhyun Kang, North Carolina State University, Raleigh, NC; Jody Cleveland, United Therapeutics Corporation, Durham, NC; Chunqin Deng, United Therapeutics Corporation, Durham, NC
|
Sample Size Calculation in Clinical Trials with Binary Co-Primary Endpoints or Multiple Testing Procedures
Zuoshun Zhang, Celgene Corporation
|
Sample Size Calculation Based on Finite Mixture Model
Zejiang Yang, INC Research
|
Sample Size Re-Estimation and Other Midcourse Adjustments with Sequential Parallel Comparison Design
Rachel Silverman, University of North Carolina; Anastasia Ivanova, UNC at Chapel Hill
|
Relative Efficiency of Unequal Versus Equal Cluster Sizes in Cluster Randomized Trials Using Generalized Estimating Equation Models
Esther Lu, Washington University School of Medicine
|
Beneath the Veneer of Healthcare Quality Measurement: Sample Size Estimation
Adeline Wilcox, Retired
|
Finite Sample Estimation in General Vector Autoregressive Processes
Mohamad Kazem Shirani Faradonbeh, University of Michigan; Ambuj Tewari, University of Michigan; George Michailidis, University of Florida
|
Sample Size and Confidence Interval Planning for Estimating the Optimal Thresholds in a Sequence of Diagnostic Tests
Christine M Schubert, Air Force Institute of Technology/ENC; Donna McClish, VCU; Amber R Wilk, Virginia Commonwealth University
9:35 AM
|
Finite Sample Estimation in General Vector Autoregressive Processes
Mohamad Kazem Shirani Faradonbeh, University of Michigan; Ambuj Tewari, University of Michigan; George Michailidis, University of Florida
9:35 AM
|
Relative Efficiency of Unequal Versus Equal Cluster Sizes in Cluster Randomized Trials Using Generalized Estimating Equation Models
Esther Lu, Washington University School of Medicine
10:35 AM
|
Sample Size Methods for Developing Predictors from Genomic Data
Kevin Dobbin, University of Georgia
10:35 AM
|
Beneath the Veneer of Healthcare Quality Measurement: Sample Size Estimation
Adeline Wilcox, Retired
11:10 AM
|
On Effect Sizes for Nonparametric Comparison of Censored Survival Outcomes
Yongzhao Shao, New York University-School of Medicine; Zhaoyin Zhu, NYU
11:50 AM
|
A Simple and Flexible Graphical Approach for Adaptive Group-Sequential Clinical Trials
Frank Bretz, Novartis AG; Toshifumi Sugitani, Astellas; Willi Maurer, Novartis
2:05 PM
|
Adaptive Multi-Arm Multi-Stage Designs
Cyrus Mehta, Cytel Inc; Pranab Ghosh, Cytel Inc, Boston University
2:25 PM
|
Accuracy in Parameter Estimation for a General Class of Effect Sizes: a Sequential Approach
Ken Kelley, University of Notre Dame; Francis B. Darku, University of Texas - Dallas; Bhargab Chattopadhyay, Indian Institute of Information Technology - Vadodara
2:35 PM
|
Sample Size Determination for Number of Patient Interviews When Developing a PRO Using Qualitative Research Based on the FDA PRO Guidance
Chris Barker, Statistical Planning and Analysis Services, Inc.
2:50 PM
|
|
Tuesday, 08/01/2017
|
Increasing and Balancing the Power of Multiple Tests in Optimal Treatment Duration Clinical Trials
Yongdong Ouyang, University of Birtish Columbia; Hubert Wong, University of British Columbia
|
Sample Size Calculation for the Generalized Poisson Regression Model Comparing Two Rates of Recurrent Events
Kimitoshi Ikeda, Amgen Astellas BioPharma K.K.
|
Sample Size Calculation to Support Local Submission
Zhuqing Yu, AbbVie; Bidan Huang, AbbVie; Jun Zhao, AbbVie Inc.; lu cui, Abbvie
|
Sample Size for Joint Testing Cause-Specific Hazard and Overall Hazard in the Presence of Competing Risks
Qing Yang, Duke University; Gang Li, University of California, Los Angeles
|
Sample Size for Joint Testing Cause-Specific Hazard and Overall Hazard in the Presence of Competing Risks
Qing Yang, Duke University; Gang Li, University of California, Los Angeles
8:40 AM
|
A Practical Bayesian Adaptive Design with Application to Cardiovascular Outcomes Trials
Matthew Psioda, UNC Chapel Hill; Joseph G Ibrahim, UNC; Mat Soukup, Center for Drug Evaluation and Research, Office of Translational Sciences, FDA
9:05 AM
|
Nonparametric Bootstrapping for Binary Hierarchical Data
Bei Wang
9:15 AM
|
Hybrid Adaptive MCMC Block Sampling
Daniel Turek, Williams College; Nicholas Michaud, University of California, Berkeley
9:35 AM
|
Sample Size Calculation for the Generalized Poisson Regression Model Comparing Two Rates of Recurrent Events
Kimitoshi Ikeda, Amgen Astellas BioPharma K.K.
9:50 AM
|
Sample Size Calculation to Support Local Submission
Zhuqing Yu, AbbVie; Bidan Huang, AbbVie; Jun Zhao, AbbVie Inc.; lu cui, Abbvie
9:55 AM
|
A Curtailed Procedure for Comparing Treatments with Binary Response with a Control
Pinyuen Chen, Syracuse University; Lifang Hsu, Le Moyne College
10:05 AM
|
The Impact of the Treatment Effect on Sample Size Estimation
Jerry Hintze, NCSS
10:35 AM
|
Use of Historical Information via Bayesian Approach in Non-Inferiority Trial: With Application in Mental Health
Samiran Ghosh, Wayne State University - Detroit, MI; Santu Ghosh, Augusta University
10:55 AM
|
Achieving Consensus on Guidance for Specifying the Target Difference in a RCT Sample Size Calculation - DELTA2 Project
William Sones, University of Oxford; Jonathan Cook, University of Oxford
10:55 AM
|
Multivariate Output Analysis for Markov Chain Monte Carlo
Galin Jones, University of Minnesota; Dootika Vats, University of Minnesota; James Flegal, University of California, Riverside
11:00 AM
|
A Review of the Sample Size Calculations of Randomised Controlled Trials Funded by One of the Leading Funders in the UK
Steven Julious, University of Sheffield; Jo Rothwell, University of Sheffield
11:15 AM
|
New DELTA2 Guidance on Specifying the Target Difference in a RCT Sample Size Calculation
Jonathan Cook, University of Oxford
11:35 AM
|
Strategies in Designing Interim Analyzes Under Discrete Random-Effects Model in a Multiregional Trial
Hsiao-Hui Tsou, National Health Research Institutes; Chi-Tian Chen, National Health Research Institutes; K. K. Gordon Lan, Janssen Pharmaceutical Companies of Johnson & Johnson; Chin-Fu Hsiao, National Health Research Institutes
11:35 AM
|
Extension of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection, and Treatment Preference Effects to Binary Outcomes
Briana Cameron, Yale University; Denise Esserman, Yale School of Public Health; Peter Peduzzi, Yale School of Public Health
12:05 PM
|
An Evaluation of Increasing Sample Size Based on Conditional Power
Michael Gaffney, Pfizer Inc.
2:05 PM
|
Efficiency Considerations for Group Sequential Designs with Adaptive Unblinded Sample Size Re-Assessment
Sam Hsiao, Cytel, Inc; Lingyun Liu, Cytel, Inc; Cyrus Mehta, Cytel Inc
2:25 PM
|
Number of Cells to Identify a Novel Subpopulation from a Single Cell RNA Sequencing
Kyung In Kim, Jackson Laboratory
2:35 PM
|
Extensions of Adaptive Sample Size Re-Estimation Methods to the Negative Binomial Setting
Mikhail Peter Salganik, Pfizer Worldwide Research & Development, Pfizer, Inc ; Sandeep Menon, Pfizer, Inc; Abigail Sloan, Harvard T.H. Chan School of Public Health
2:45 PM
|
Implementation of Promising Zone Methodology in a Ph 3 Trial in AML (VALOR)
Jennifer Smith, Sunesis
3:25 PM
|
Power Analysis and Sample Determination in Dynamic Risk Prediction
Zhaowen Sun; Chung-Chou H. Chang, University of Pittsburgh
3:35 PM
|
|
Wednesday, 08/02/2017
|
Unblinded Sample Size Re-Estimation for Complex Trials
Chris Holland, Amgen
|
Designing a Robust Monitoring Scheme for Natural Resources at a Continental Scale
Emily L Weiser, U.S. Geological Survey; James E. Diffendorfer, U.S. Geological Survey; Laura López-Hoffman, The University of Arizona; Darius J Semmens, U.S. Geological Survey; Wayne E Thogmartin, U.S. Geological Survey
8:55 AM
|
Sample Size Calculation in Confirmatory Subgroup Analyses
Dong Xi, Novartis Pharmaceuticals Corporation; Frank Bretz, Novartis AG; Ekkehard Glimm, Novartis
9:15 AM
|
Observed Prior Information
David Jones, SAMSI / Duke; Yang Chen, Harvard University; Xiao-Li Meng, Harvard University
9:20 AM
|
Balancing Bias, Precision, and Sample Size Recovered in Determining a Practical Missing Data Imputation Approach
Laney Light; Frost Hubbard, IMPAQ International, LLC; Katherine Harris, IMPAQ International, LLC
9:20 AM
|
Bayesian Approach of Assessing Non-Inferiority of a New Treatment with Binary Outcomes in a Three-Arm Trial
Shrabanti Chowdhury; Samiran Ghosh, Wayne State University - Detroit, MI; Ram Tiwari, FDA/CDER/OT/OB
2:05 PM
|
Simulation Considerations for Multistage Adaptive Designs and Designs with Sample Size Re-Estimation: Type 1 Error Control and Beyond
Greg Cicconetti, Abbvie; Sergei Leonov, ICON Clinical Research; Yili L Pritchett, MedImmune; Michael Smith, Astellas; Alan Hartford, AbbVie
2:45 PM
|
Survey Designs with Small Stratum Sample Sizes
Xiaofei Zhang, Iowa State University; Emily Berg, Iowa State University; Wayne A. Fuller, Iowa State University
3:20 PM
|
|
|
